MEGAPTH Indications/Uses

Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture: Teriparatide (rDNA origin) injection is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, teriparatide (rDNA origin) injection reduces the risk of vertebral and nonvertebral fractures.
Increase of Bone Mass in Men with Primary or Hypogonadal Osteoporosis at High Risk for Fracture: Teriparatide (rDNA origin) injection is indicated to increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patents who have failed or are intolerant to other available osteoporosis therapy.
Treatment of Men and Women with Glucocorticoid-Induced Osteoporosis at High Risk for Fracture: Teriparatide injection is indicated for the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.